🇺🇸 FDA
Pipeline program

Bavencio 20 mg/mL concentrate for solution for infusion

MS100070_0176

Phase 3 small_molecule active

Quick answer

Bavencio 20 mg/mL concentrate for solution for infusion for Solid Tumors is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Solid Tumors
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials